Hong Kong healthtech stocks fall on profit-taking, Microsoft healthcare push

Published 09/10/2025, 05:54
© Reuters.

Investing.com-- Hong Kong-listed healthtech and healthcare stocks fell on Thursday as investors locked-in profits from a strong run, while reports of Microsoft developing products for the sector also spooked markets. 

Alibaba Health Information Technology Ltd (HK:0241) and Jd Health International Inc (HK:6618), the healthtech arms of the eponymous e-commerce giants, fell 3.3% and 4.3%, respectively. The two have roughly doubled in value so far in 2025

Ping An Healthcare and Technology Company Ltd (HK:1833) shed 1%, while Akeso Inc (HK:9926) fell 5.1%. 

Broader healthcare stocks also declined, with Sino Biopharmaceutical Ltd (HK:1177) and Hansoh Pharmaceutical Group Co Ltd (HK:3692) losing 6.4% and 5%, respectively. The stocks were the worst performers on the Hang Seng, which traded flat after losing as much as 1%. 

CK Life Sciences Intl Holdings Inc (HK:0775) was an outlier, rising 5% after it agreed to merge its unit, Polynoma, with Nasdaq-listed Transcode Therapeutics Inc (NASDAQ:RNAZ). 

Jefferies analysts attributed the losses to profit-taking, noting that investors were also pivoting into tech stocks after a "massive rally" in pharma and healthcare stocks so far in 2025. 

Adding to pressure on healthtech stocks was a Wall Street Journal report on Microsoft Corporation (NASDAQ:MSFT) pushing further into the sector. 

Microsoft entered a deal with Harvard to improve health content on its Copilot AI assistant, the WSJ reported on Wednesday. 

Microsoft AI’s vice president of health, Dominic King, told the WSJ that the company intends to make Copilot serve health-related answers that are more in line with information from a medical practitioner than anything currently on offer.

A greater healthcare push from Microsoft could herald more competition for Chinese healthtech firms, especially in markets outside the mainland. 

Earlier this year, Microsoft said an AI tool it developed was able to diagnose diseases at a rate four times more accurate than a group of doctors, at a fraction of the price. 

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.